Immucell (ICCC) EBT Margin (2010 - 2026)

Immucell (ICCC) has reported EBT Margin for 17 consecutive years, with 26.17% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT Margin rose 1835.0% year-over-year to 26.17%; the trailing twelve-month figure through Jun 2026 stood at 2.23% (down 850.0% YoY), and the FY2025 full-year result was 3.72%, up 438.0% from the prior year.
• EBT Margin climbed to 26.17% in Q2 2026 per ICCC's latest filing, from 37.32% in the prior quarter.
• Across five years, EBT Margin topped out at 26.17% in Q2 2026 and bottomed at 67.13% in Q1 2023.
• Historically, EBT Margin has averaged 13.47% across 5 years, with a median of 12.61% in 2024.
• The sharpest annual moves came in 2023 and 2024: EBT Margin slumped 7570 bps in 2023, then jumped 6111 bps in 2024.
• Over 5 years, EBT Margin stood at 42.61% in 2022, then jumped by 59 bps to 17.41% in 2023, then soared by 139 bps to 6.72% in 2024, then sank by 656 bps to 37.32% in 2025, then soared by 170 bps to 26.17% in 2026.
• According to Business Quant data, EBT Margin over the past three periods registered 26.17%, 37.32%, and 2.46% for Q2 2026, Q4 2025, and Q3 2025 respectively.